Equities

Legend Biotech Corp

Legend Biotech Corp

Actions
  • Price (EUR)45.40
  • Today's Change0.20 / 0.44%
  • Shares traded--
  • 1 Year change-24.96%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:07 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1,3091,027884
Total Receivables, Net1574658
Total Inventory19101.75
Prepaid expenses12165.95
Other current assets, total------
Total current assets1,4981,099950
Property, plant & equipment, net189161141
Goodwill, net------
Intangibles, net4.063.414.68
Long term investments------
Note receivable - long term0.740.912.17
Other long term assets4.361.4922
Total assets1,8491,3311,119
LIABILITIES
Accounts payable20337.04
Accrued expenses102149101
Notes payable/short-term debt000
Current portion long-term debt/capital leases3.183.560.91
Other current liabilities, total91112121
Total current liabilities216298229
Total long term debt325281122
Total debt329285123
Deferred income tax----0
Minority interest------
Other liabilities, total557.892.26
Total liabilities597587354
SHAREHOLDERS EQUITY
Common stock0.040.030.03
Additional paid-in capital------
Retained earnings (accumulated deficit)1,251744766
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total------
Total equity1,251744766
Total liabilities & shareholders' equity1,8491,3311,119
Total common shares outstanding364330--
Treasury shares - common primary issue------
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.